Figure 1.
Flowchart of studies included in meta-analysis. RCT, randomized controlled trial.
Table 1.
Baseline characteristics of the head-to-head studies comparing ranibizumab with bevacizumab.
Table 2.
Outcome data of randomized controlled trials included in the meta-analysis.
Figure 2.
Risk ratio of thromboembolic events associated with intravitreal bevacizumab compared with ranibizumab.
Each study is shown by the point estimate of relative risk “risk ratio” (RR) - the size of the square is proportional to the weight of the study - and 95%confidence interval for the RR (lines extending from the squares); the pooled RR and 95%confidence interval are shown as a diamond.
Table 3.
Risk ratio of systemic adverse events associated with intravitreal bevacizumab compared with ranibizumab.
Table 4.
Summary of high-quality non-randomized studies comparing ranibizumab with bevacizumab.